Trial · NCT02783300
Participant flow243
How many started, completed or left each group, period by period.
61 to 80 of 243
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 1: GSK3326595 400mg QD | 6 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 1: GSK3326595 600mg QD | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 1: GSK3326595 50mg Twice Daily (BID) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 1: GSK3326595 100mg BID | 1 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 1: GSK3326595 150mg BID | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 1: GSK3326595 200mg BID | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 1: GSK3326595 300mg QD (Food Effect) | 7 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (TNBC) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (mTCC) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (GBM) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (ER+BC) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (HPV+) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (ACC) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 300mg (ACC) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (NHL P53 Mutant) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 300mg (NHL P53 Mutant) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (NHL P53 Wild Type) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 300mg (NHL P53 Wild Type) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 400mg (NHL P53 Unknown) | 0 | |
| Part 1- Dose Escalation Phase | NOT COMPLETED | Part 2: GSK3326595 300mg (NSCLC) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02783300/flow?page=4